# Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2

> **NCT01884961** · PHASE2 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer
- Malignant Melanoma, Metastatic

## Interventions

- **OTHER:** Boost of radiotherapy + high dose IL-2 treatment

## Key facts

- **NCT ID:** NCT01884961
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-09
- **Primary completion:** 2021-06
- **Final completion:** 2025-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884961, "Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01884961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*